Nanoviricides Inc (NNVC)
1.89
+0.06
(+3.28%)
USD |
NYAM |
May 10, 16:00
1.88
-0.01
(-0.53%)
After-Hours: 20:00
Nanoviricides SG&A Expense (Quarterly): 0.6109M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.6109M |
September 30, 2023 | 0.5649M |
June 30, 2023 | 0.7634M |
March 31, 2023 | 0.6146M |
December 31, 2022 | 0.6633M |
September 30, 2022 | 0.5097M |
June 30, 2022 | 0.6212M |
March 31, 2022 | 0.5328M |
December 31, 2021 | 0.6593M |
September 30, 2021 | 0.5154M |
June 30, 2021 | 0.4902M |
March 31, 2021 | 0.6434M |
December 31, 2020 | 0.7987M |
September 30, 2020 | 0.6973M |
June 30, 2020 | 0.7649M |
March 31, 2020 | 1.408M |
December 31, 2019 | 0.6223M |
September 30, 2019 | 0.5055M |
June 30, 2019 | 0.5819M |
March 31, 2019 | 0.7726M |
December 31, 2018 | 0.7114M |
September 30, 2018 | 0.6276M |
June 30, 2018 | 0.7518M |
March 31, 2018 | 1.127M |
December 31, 2017 | 0.7541M |
Date | Value |
---|---|
September 30, 2017 | 0.7785M |
June 30, 2017 | -0.0467M |
March 31, 2017 | 1.056M |
December 31, 2016 | 1.037M |
September 30, 2016 | 0.9883M |
June 30, 2016 | 0.894M |
March 31, 2016 | 0.9807M |
December 31, 2015 | 0.9378M |
September 30, 2015 | 0.943M |
June 30, 2015 | 1.217M |
March 31, 2015 | 0.5762M |
December 31, 2014 | 0.7872M |
September 30, 2014 | 0.876M |
June 30, 2014 | 1.593M |
March 31, 2014 | 0.6076M |
December 31, 2013 | 0.6209M |
September 30, 2013 | 0.7146M |
June 30, 2013 | 0.5489M |
March 31, 2013 | 0.8314M |
December 31, 2012 | 0.5334M |
September 30, 2012 | 0.3812M |
June 30, 2012 | 0.5341M |
March 31, 2012 | 0.4941M |
December 31, 2011 | 0.3256M |
September 30, 2011 | 0.4487M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.4902M
Minimum
Jun 2021
1.408M
Maximum
Mar 2020
0.6615M
Average
0.6212M
Median
Jun 2022
SG&A Expense (Quarterly) Benchmarks
EyePoint Pharmaceuticals Inc | 11.43M |
Enanta Pharmaceuticals Inc | 14.24M |
GlycoMimetics Inc | 4.312M |
FibroGen Inc | 22.82M |
Corvus Pharmaceuticals Inc | 2.178M |